Filing Flows › Globus Medical (GMED) › Q3 2026 › vs Q2 2026
Globus Medical (GMED) Q3 2026 vs Q2 2026 (quarter over quarter)
Globus Medical's revenue fell $25.9M (-3%) from $790M in Q2 2026 to $764M in Q3 2026. The biggest changes: Musculoskeletal Solutions −$34.7M (-5%); Enabling Technologies +$8.8M (+34%). Operating margin 23.2% against 23.1% (+0.1 pts).
Globus Medical, Q3 2026: revenue $764M (-0.7% year over year), operating margin 23.2%, net earnings $141M, operating cash flow $265M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 23.2% | 23.1% | +0.1 pts |
| Net margin | 18.5% | 19.2% | -0.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Musculoskeletal Solutions | $729M | $764M | −$34.7M | -5% |
| Enabling Technologies | $34.9M | $26.1M | $8.8M | +34% |
| Revenue | $764M | $790M | −$25.9M | -3% |
| Other income, net | $5.7M | $7.4M | −$1.7M | -23% |
| Operating profit | $178M | $182M | −$4.9M | -3% |
| Costs & expenses | $586M | $607M | −$21.0M | -3% |
| Pre-tax earnings | $183M | $190M | −$6.5M | -3% |
| Cost of revenue | $233M | $241M | −$8.5M | -4% |
| Research & development | $34.5M | $36.3M | −$1.8M | -5% |
| SG&A | $288M | $287M | $1.6M | +0.6% |
| Other operating costs | $30.3M | $42.6M | −$12.3M | -29% |
| Net earnings | $141M | $152M | −$10.4M | -7% |
| Income tax | $42.1M | $38.2M | $3.8M | +10% |
| Depreciation & amortization | $70.4M | $69.5M | $876K | +1% |
| Share-based compensation | $11.7M | $13.4M | −$1.6M | -12% |
| Working capital & other | $41.9M | −$24.7M | $66.6M | — |
| Operating cash flow | $265M | $210M | $55.5M | +26% |
Questions
How much did Globus Medical's revenue grow quarter over quarter in Q3 2026?
Globus Medical's revenue fell $25.9M (-3%) from $790M in Q2 2026 to $764M in Q3 2026.
What drove Globus Medical's revenue change in Q3 2026?
Musculoskeletal Solutions −$34.7M (-5%); Enabling Technologies +$8.8M (+34%).